COMPOSITIONS AND METHODS FOR EYE HEALTH COMPRISING VERY LONG CHAIN FATTY ACIDS

1 . A composition for visual health comprising at least one very long chain fatty acid chosen from C 26+ acids (5n-3), prodrugs thereof, and pharmaceutically acceptable salts of any of the foregoing.

2 . The composition of claim 1 , wherein the composition comprises 1 mg to 1000 mg of the at least one very long chain fatty acid chosen from C 26+ acids (5n-3) or an equivalent amount of a prodrug, pharmaceutically acceptable salt, and/or pharmaceutically acceptable salt of a prodrug of at least one very long chain fatty acid chosen from C 26+ acids (5n-3).

3 . The composition of claim 1 , wherein the composition comprises 10 mg to 500 mg of the at least one very long chain fatty acid chosen from C 26+ acids (5n-3) or an equivalent amount of a prodrug, pharmaceutically acceptable salt, and/or pharmaceutically acceptable salt of a prodrug of at least one very long chain fatty acid chosen from C 26+ acids (5n-3).

4 . The composition of claim 1 , wherein the composition comprises 25 mg to 100 mg of the at least one very long chain fatty acid chosen from C 26+ acids (5n-3) or an equivalent amount of a prodrug, pharmaceutically acceptable salt, and/or pharmaceutically acceptable salt of a prodrug of at least one very long chain fatty acid chosen from C 26+ acids (5n-3).

5 . The composition of claim 1 , wherein the composition comprises 40 mg of at least one very long chain fatty acid chosen from C 26+ acids (5n-3) or an equivalent amount of prodrugs, pharmaceutically acceptable salts, and/or pharmaceutically acceptable salts of prodrugs of C 26+ acid (5n-3) groups.

6 . The composition of claim 1 , wherein the C 26+ acids (5n-3) is a C 26 acid (5n-3), C 28 acid (5n-3), C 30 acid (5n-3), C 32 acid (5n-3), and/or C 34 acid (5n-3).

7 . The composition of claim 1 , wherein the composition further comprises at least one additional component chosen from:

at least one very long chain fatty acid chosen from C 26+ acids (6n-3), prodrugs thereof, pharmaceutically acceptable salts thereof, and pharmaceutically acceptable salt of a prodrug of at least one very long chain fatty acid chosen from C 26+ acids (6n-3).

docosahexanoic acid, prodrugs thereof, and/or pharmaceutically acceptable salts of any of the foregoing;

eicosapentanoic acid, prodrugs thereof, and/or pharmaceutically acceptable salts of any of the foregoing;

vitamin C, prodrugs thereof, and/or pharmaceutically acceptable salts of any of the foregoing;

vitamin E, prodrugs thereof, and/or pharmaceutically acceptable salts of any of the foregoing;

zinc, prodrugs thereof, and/or pharmaceutically acceptable salts of any of the foregoing;

copper, prodrugs thereof, and/or pharmaceutically acceptable salts of any of the foregoing;

lutein, prodrugs thereof, and/or pharmaceutically acceptable salts of any of the foregoing; and

zeaxanthin, prodrugs thereof, and/or pharmaceutically acceptable salts of any of the foregoing.

8 . The composition of claim 1 , wherein the composition further comprises 20 mg to 350 mg of docosahexanoic acid or an equivalent amount of a prodrug, a pharmaceutically acceptable salt, and/or a pharmaceutically acceptable salt of a prodrug of docosahexanoic acid.

9 . The composition of claim 1 , wherein the composition further comprises 20 mg to 650 mg of eicosapentanoic acid or an equivalent amount of a prodrug, a pharmaceutically acceptable salt, and/or a pharmaceutically acceptable salt of a prodrug of eicosapentanoic acid.

10 . The composition of claim 1 , wherein the composition further comprises 350 mg to 800 mg of vitamin C or an equivalent amount of a prodrug, a pharmaceutically acceptable salt, and/or a pharmaceutically acceptable salt of a prodrug of vitamin C.

11 . The composition of claim 1 , wherein the composition further comprises 50 mg to 550 mg of vitamin E or an equivalent amount of a prodrug, a pharmaceutically acceptable salt, and/or a pharmaceutically acceptable salt of a prodrug of vitamin E.

12 . The composition of claim 1 , wherein the composition further comprises 20 mg to 90 mg of zinc or an equivalent amount of a prodrug, a pharmaceutically acceptable form, and/or a pharmaceutically acceptable salt of a prodrug of zinc.

13 . The composition of claim 1 , wherein the composition further comprises 1.5 mg to 2.5 mg of copper or an equivalent amount of a prodrug, a pharmaceutically acceptable form, and/or a pharmaceutically acceptable salt of a prodrug of copper.

14 . The composition of claim 1 , wherein the composition further comprises 5 mg to 50 mg of lutein or an equivalent amount of a prodrug, a pharmaceutically acceptable salt, and/or a pharmaceutically acceptable salt of a prodrug of lutein.

15 . The composition of claim 1 , wherein the composition comprises 1 mg to 20 mg of zeaxanthin or an equivalent amount of a prodrug, a pharmaceutically acceptable salt, and/or a pharmaceutically acceptable salt of a prodrug of zeaxanthin.

16 . The composition of claim 1 , wherein the composition comprises: optionally 1 mg to 200 mg at least one C 26+ acid (6n-3) or an equivalent amount of a prodrug, pharmaceutically acceptable salt, and/or pharmaceutically acceptable salt of a prodrug of at least one C 26+ acid (6n-3); 40 mg at least one C 26+ acid (5n-3) or an equivalent amount of a prodrug, pharmaceutically acceptable salt, and/or pharmaceutically acceptable salt of a prodrug of at least one C 26+ acid (5n-3); 200 mg docosahexanoic acid or an equivalent amount of a prodrug, pharmaceutically acceptable salt, and/or pharmaceutically acceptable salt of a prodrug of docosahexanoic acid; and 40 mg eicosapentanoic acid or an equivalent amount of a prodrug, pharmaceutically acceptable salt, and/or pharmaceutically acceptable salt of a prodrug of eicosapentanoic acid.

17 . The composition of claim 1 , wherein the composition comprises: optionally 1 mg to 200 mg C 26+ acid (6n-3) or an equivalent amount of a prodrug, pharmaceutically acceptable salt, and/or pharmaceutically acceptable salt of a prodrug of C 26+ acid (6n-3); 40 mg at least one C 26-34 acid (5n-3) or an equivalent amount of a prodrug, pharmaceutically acceptable salt, and/or pharmaceutically acceptable salt of a prodrug of at least one C 26-34 acid (5n-3); 200 mg docosahexanoic acid or an equivalent amount of a prodrug, pharmaceutically acceptable salt, and/or pharmaceutically acceptable salt of a prodrug of docosahexanoic acid; and 40 mg eicosapentanoic acid or an equivalent amount of a prodrug, pharmaceutically acceptable salt, and/or pharmaceutically acceptable salt of a prodrug of eicosapentanoic acid.

18 . The composition of claim 1 , wherein the composition comprises: 500.0 mg vitamin C or an equivalent amount of a prodrug, pharmaceutically acceptable salt, and/or pharmaceutically acceptable salt of a prodrug of vitamin C; 180.0 mg vitamin E or an equivalent amount of a prodrug, pharmaceutically acceptable salt, and/or pharmaceutically acceptable salt of a prodrug of vitamin E; 80.0 mg zinc or an equivalent amount of a prodrug, pharmaceutically acceptable salt, and/or pharmaceutically acceptable salt of a prodrug of zinc; 2.0 mg copper or an equivalent amount of a prodrug, pharmaceutically acceptable salt, and/or pharmaceutically acceptable salt of a prodrug of zinc; up to 200.0 mg at least one C 26+ acid (6n-3) or an equivalent amount of a prodrug, pharmaceutically acceptable salt, and/or pharmaceutically acceptable salt of a prodrug of at least one C 26+ acid (6n-3); 200.0 mg docosahexanoic acid or an equivalent amount of a prodrug, pharmaceutically acceptable salt, and/or pharmaceutically acceptable salt of a prodrug of docosahexanoic acid; 40.0 mg at least one C 26+ acid (5n-3); and 40.0 mg eicosapentanoic acid or an equivalent amount of a prodrug, pharmaceutically acceptable salt, and/or pharmaceutically acceptable salt of a prodrug of eicosapentanoic acid.

19 . The composition of claim 1 , wherein the composition comprises: 500.0 mg vitamin C or an equivalent amount of a prodrug, pharmaceutically acceptable salt, and/or pharmaceutically acceptable salt of a prodrug of vitamin C; 180.0 mg vitamin E or an equivalent amount of a prodrug, pharmaceutically acceptable salt, and/or pharmaceutically acceptable salt of a prodrug of vitamin E; 80.0 mg zinc or an equivalent amount of a prodrug, pharmaceutically acceptable salt, and/or pharmaceutically acceptable salt of a prodrug of zinc; 2.0 mg copper or an equivalent amount of a prodrug, pharmaceutically acceptable salt, and/or pharmaceutically acceptable salt of a prodrug of copper; up to 200.0 mg C 26+ acid (6n-3) or an equivalent amount of a prodrug, pharmaceutically acceptable salt, and/or pharmaceutically acceptable salt of a prodrug of C 26+ acid (6n-3); 200 mg docosahexanoic acid or an equivalent amount of a prodrug, pharmaceutically acceptable salt, and/or pharmaceutically acceptable salt of a prodrug of docosahexanoic acid; 40.0 mg at least one C 26-34 acid (5n-3) or an equivalent amount of a prodrug, pharmaceutically acceptable salt, and/or pharmaceutically acceptable salt of a prodrug of C 26-34 acid (5n-3); and 40.0 mg eicosapentanoic acid or an equivalent amount of a prodrug, pharmaceutically acceptable salt, and/or pharmaceutically acceptable salt of a prodrug of eicosapentanoic acid.

20 . The composition of claim 18 , further comprising 10.0 mg lutein or an equivalent amount of a prodrug, pharmaceutically acceptable salt, and/or pharmaceutically acceptable salt of a prodrug of lutein and 2.0 mg zeaxanthin or an equivalent amount of a prodrug, pharmaceutically acceptable salt, and/or pharmaceutically acceptable salt of a prodrug of zeaxanthin.

21 . The composition of claim 1 , further comprising at least one additional active ingredient.

22 . The composition of claim 21 , wherein the at least one additional active ingredient is chosen from

Vitamin C, prodrugs thereof, and pharmaceutically acceptable salts of any of the foregoing;

Vitamin E, prodrugs thereof, and pharmaceutically acceptable salts of any of the foregoing;

zinc, prodrugs thereof, and pharmaceutically acceptable salts of any of the foregoing;

copper, prodrugs thereof, and pharmaceutically acceptable salts of any of the foregoing;

Vitamin B1, prodrugs thereof, and pharmaceutically acceptable salts of any of the foregoing;

Vitamin B2, prodrugs thereof, and pharmaceutically acceptable salts of any of the foregoing;

Vitamin B3, prodrugs thereof, and pharmaceutically acceptable salts of any of the foregoing;

Vitamin B5, prodrugs thereof, and pharmaceutically acceptable salts of any of the foregoing;

Vitamin B6, prodrugs thereof, and pharmaceutically acceptable salts of any of the foregoing;

Vitamin B7, prodrugs thereof, and pharmaceutically acceptable salts of any of the foregoing;

Vitamin B9, prodrugs thereof, and pharmaceutically acceptable salts of any of the foregoing;

Vitamin B12, prodrugs thereof, and pharmaceutically acceptable salts of any of the foregoing;

lutein, prodrugs thereof, and pharmaceutically acceptable salts of any of the foregoing; and

zeaxanthin, prodrugs thereof, and pharmaceutically acceptable salts of any of the foregoing.

23 . The composition of claim 1 , wherein the composition is in the form of one or more tablets, capsules, soft gels, liquid, or powder.

24 . The composition of claim 1 , wherein the composition is a daily dosage.

25 . A method of delaying the progression and/or onset macular degeneration, the method comprising administering to a subject in need thereof a composition according to claim 1 .

26 . A method for treating and/or preventing at least one disease, disorder, and/or condition associated with a loss of visual acuity, the method comprising administering to a subject a composition according to claim 1 .

27 . The method of claim 25 , wherein the composition is administered daily to the subject in one, two, three, or four daily doses.